Table of Contents

doi : 10.1016/S0923-7534(22)01180-2

Volume 33, Issue 7, July 2022, Pages i-ii

خرید پکیج و مشاهده آنلاین مقاله

Editorial Board

doi : 10.1016/S0923-7534(22)01181-4

خرید پکیج و مشاهده آنلاین مقاله

Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers—ready for prime time?

S.Arulananda12E.Segelov12

doi : 10.1016/j.annonc.2022.04.008

خرید پکیج و مشاهده آنلاین مقاله

Bigger isn't always better: the ESMO dose de-intensification guideline framework

C.L.Shapiro

doi : 10.1016/j.annonc.2022.05.001

خرید پکیج و مشاهده آنلاین مقاله

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer

S.Filetti1C.Durante2D.M.Hartl34S.Leboulleux56L.D.Locati78K.Newbold9M.G.Papotti10A.Berruti11ESMO Guidelines Committee

doi : 10.1016/j.annonc.2022.04.009

خرید پکیج و مشاهده آنلاین مقاله

Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial

U.T.Hacker1†D.Hasenclever2†R.Baber34N.Linder5H.Busse5R.Obermannova67L.Zdrazilova-Dubska78D.Valik78F.Lordick1

doi : 10.1016/j.annonc.2022.03.274

خرید پکیج و مشاهده آنلاین مقاله

The age-dependent association of risk factors with pancreatic cancer

C.Yuan1J.Kim2Q.L.Wang1A.A.Lee3A.Babic1

doi : 10.1016/j.annonc.2022.03.276

خرید پکیج و مشاهده آنلاین مقاله

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification

D.Trapani12†M.A.Franzoi3†H.J.Burstein2L.A.Carey4S.Delaloge5N.Harbeck6D.F.Hayes7K.Kalinsky8L.Pusztai9M.M.Regan10I.Sestak11T.Spanic12J.Sparano13S.Jezdic14N.Cherny15G.Curigliano16F.Andre3

doi : 10.1016/j.annonc.2022.03.273

خرید پکیج و مشاهده آنلاین مقاله

Cancer risk in individuals with autism spectrum disorder

Q.Liu1W.Yin1J.J.Meijsen2A.Reichenberg34J.R.Gådin2A.J.Schork2H.-O.Adami567A.Kolevzon348S.Sandin345†F.Fang1†

doi : 10.1016/j.annonc.2022.04.006

خرید پکیج و مشاهده آنلاین مقاله

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)

A.Zer1O.Icht2L.Yosef2D.Avram2O.Jacobi2E.Fenig2N.Kurman2I.Peretz2S.Shamai³O.Merimsky³E.Ben-Ami�R.Shapira Frommer�A.E.Schwarzbach5H.Bernstine6R.Weitzen7O.Vornicova8G.Bar-Sela8S.M.Stemmer2M.Lotem9

doi : 10.1016/j.annonc.2022.03.012

خرید پکیج و مشاهده آنلاین مقاله

HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade

X.M.Shao12J.Huang1N.Niknafs3A.Balan3C.Cherry3J.White3V.E.Velculescu13V.Anagnostou3R.Karchin123

doi : 10.1016/j.annonc.2022.03.013

خرید پکیج و مشاهده آنلاین مقاله

Reply to the Letter to the Editor ‘Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer’ by A. Okines and N. Turner

C.E.GeyerJr.1W.M.Sikov2S.Loibl3

doi : 10.1016/j.annonc.2022.03.275

خرید پکیج و مشاهده آنلاین مقاله

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

F.Nelli1D.Giannarelli2A.Fabbri1M.A.Silvestri3J. R. GironBerrios1A.Virtuoso1E.Marrucci1M.Schirripa1M.Mazzotta1A.Onorato1V.Panichi3G.Topini3G.Pessina4F.Natoni4C.Signorelli1M.G.Chilelli1F.Primi1E.M.Ruggeri1

doi : 10.1016/j.annonc.2022.04.002

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study�: [Annals of Oncology (2019), volume 30:1279-1288]

S.Loibl12M.Untch3N.Burchardi1J.Huober4B.V.Sinn56J.-U.Blohmer7E.-M.Grischke8J.Furlanetto1H.Tesch2C.Hanusch9K.Engels10M.Rezai11C.Jackisch12W.D.Schmitt5G.von Minckwitz1J.Thomalla13S.Kümmel14B.Rautenberg15…A.Schneeweiss18

doi : 10.1016/j.annonc.2022.04.003

خرید پکیج و مشاهده آنلاین مقاله